Comparison of efficacy, safety and costs between half-fluence and half-dose photodynamic therapy for Chronic Central Serous Chorioretinopathy
Détails
ID Serval
serval:BIB_131B0037F4BB
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
Comparison of efficacy, safety and costs between half-fluence and half-dose photodynamic therapy for Chronic Central Serous Chorioretinopathy
Titre de la conférence
ARVO Annual Meeting
Organisation
2013 ARVO Annual Meeting. Seattle, WA, USA
Adresse
2013 ARVO Annual Meeting. Seattle, WA, USA – 30 aprile – 5 maggio 2013.
Statut éditorial
Publié
Date de publication
30/04/2013
Peer-reviewed
Oui
Volume
54
Pages
2797
Langue
anglais
Notes
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2797
Résumé
Purpose: To compare the short-term and long-term efficacy, safety and costs of half-fluence and half-dose photodynamic therapy (PDT) in chronic central serous chorioretinopathy (CSC).
Methods: Multicenter retrospective comparison study of 56 patients affected by chronic CSC, including 28 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and resolution of subretinal fluid on optical coherence tomography at 1 month and at the last-follow-up visit (LFU) were assessed. Cost analysis was also performed.
Results: Snellen BCVA improved significantly (p<0.001) both in the half-fluence group from 0.70 (±0.23) to 0.87 (±0.21) and in the half-dose group from 0.76 (±0.16) to 0.87 (±0.16) at the LFU. There was no difference in final BCVA between the 2 groups. At 1 month a complete resolution of subretinal fluid was observed in 19 (61.3%) half-fluence treated eyes and in 25 (86.2%) half-dose treated eyes (p =0.04). At the LFU, a complete resolution of sub-retinal fluid was achieved in 26 (83.9%) half-fluence treated eyes and 29 (100%) half-dose treated eyes (p = 0.0529; OR, 5.20; 95% CI, 1.75-15.42). Nine (25.8%) eyes in the half-fluence group and 5 (17.2%) eyes in the half-dose group had at least one recurrent episode of subretinal fluid (OR, 1.96; 95% CI, 0.57-6.76). Overall there were 15 and 5 recurrences in the half-fluence PDT and half-dose PDT respectively (p=0.06; OR, 4.5; 95% CI, 1.36-14.84). The overall cost of half-fluence PDT was twice the cost of half-dose PDT.
Conclusions: Half-dose PDT induced a more rapidly reabsorption of the fluid, a more lasting effect and a halving of the costs respect to half-fluence PDT
Methods: Multicenter retrospective comparison study of 56 patients affected by chronic CSC, including 28 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and resolution of subretinal fluid on optical coherence tomography at 1 month and at the last-follow-up visit (LFU) were assessed. Cost analysis was also performed.
Results: Snellen BCVA improved significantly (p<0.001) both in the half-fluence group from 0.70 (±0.23) to 0.87 (±0.21) and in the half-dose group from 0.76 (±0.16) to 0.87 (±0.16) at the LFU. There was no difference in final BCVA between the 2 groups. At 1 month a complete resolution of subretinal fluid was observed in 19 (61.3%) half-fluence treated eyes and in 25 (86.2%) half-dose treated eyes (p =0.04). At the LFU, a complete resolution of sub-retinal fluid was achieved in 26 (83.9%) half-fluence treated eyes and 29 (100%) half-dose treated eyes (p = 0.0529; OR, 5.20; 95% CI, 1.75-15.42). Nine (25.8%) eyes in the half-fluence group and 5 (17.2%) eyes in the half-dose group had at least one recurrent episode of subretinal fluid (OR, 1.96; 95% CI, 0.57-6.76). Overall there were 15 and 5 recurrences in the half-fluence PDT and half-dose PDT respectively (p=0.06; OR, 4.5; 95% CI, 1.36-14.84). The overall cost of half-fluence PDT was twice the cost of half-dose PDT.
Conclusions: Half-dose PDT induced a more rapidly reabsorption of the fluid, a more lasting effect and a halving of the costs respect to half-fluence PDT
Mots-clé
choroid • photodynamic therapy • macula/fovea
Site de l'éditeur
Création de la notice
30/06/2021 10:43
Dernière modification de la notice
09/07/2021 6:37